Incidence and management of chemotherapy-induced nausea and vomiting in women with breast cancer

Gozzo, Thais de Oliveira; Souza, Sarah Gomes de; Moysés, Aline Maria Bonini; Panobianco, Marislei Sanches; Almeida, Ana Maria de.
Rev. gaúch. enferm ; 35(3): 117-123, Sep/2014. tab
Artigo em Inglês | LILACS, BDENF - enfermagem (Brasil) | ID: lil-725732

Documentos relacionados

  1. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
  2. The emerging emetogenicity of trifluridine/tipiracil (TAS­102) from patient self-reporting: a multicenter, prospective, observational study.
  3. Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting.
  4. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis.
  5. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
  6. [Incidence and management of chemotherapy-induced nausea and vomiting in women with breast cancer].
  7. The antiemetic actions of GIP receptor agonism.
  8. 5HT<sub>3</sub> RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer.
  9. Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting.
  10. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.